The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preliminary results of a phase II study of surufatinib plus sintilimab, nab-paclitaxel and gemcitabine (AG) as first-line therapy in patients (pts) with locally advanced or metastatic pancreatic adenocarcinoma (mPDAC).
 
Dong-Sheng Zhang
No Relationships to Disclose
 
Fu-Rong Liu
Consulting or Advisory Role - KYM Biosciences
 
Yun-Xin Lu
No Relationships to Disclose
 
Bing Bai
No Relationships to Disclose
 
Yang Zhang
No Relationships to Disclose
 
Zhi-Qiang Wang
No Relationships to Disclose
 
Yu Liu
No Relationships to Disclose
 
Jian-Wen Chen
No Relationships to Disclose
 
Feng Wang
No Relationships to Disclose
 
Rui-Hua Xu
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; BeiGene; Bristol-Myers Squibb; HenRui; Junshi Biosciences; KYM Biosciences; Merck Serono; Roche